Discover
bimekizumab (UCB4940) / UCBA Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) (clinicaltrials.gov) - Sep 15, 2020 - P3; N=172; Completed; Sponsor: UCB Biopharma S.P.R.L.; Active, not recruiting --> Completed; N=38 --> 172 Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimAbbVie brings together 300 dermatologists in a virtual meeting [Google translation] (Murcia.com) - Sep 17, 2020 - "The biopharmaceutical company AbbVie brings together 300 dermatologists in a virtual meeting to share scientific evidence and clinical development, on the occasion of the marketing in Spain of SKYRIZI® (risankizumab) for the treatment of moderate to severe plaque psoriasis in adult patients candidates for systemic treatment....Throughout this meeting, the different studies that have shown efficacy rates significantly higher than other mechanisms of action of biological drugs already existing today will be shared, in the primary and secondary objectives analyzed, as well as a favorable safety profile will be shared." belumosudil (KD025 ) / Kadmon, Romeck PharmaKD025: Patent expiry in 2035 (Kadmon, 22nd Annual H.C. Wainwright Global Investment Conference 2020 (Virtual Meeting)) - Sep 15, 2020Patent [Screenshot]
